Syntr Health Technologies intends to expand the SyntrFuge system into various aesthetic indications.
Syntr Health Technologies, Inc.’s SyntrFuge automated fat processing system corrects moderate-to-severe mid-face and nasolabial fold volume deficits, according to interim results from a post-market facial fat transfer clinical study.
The company participated in Octane’s Aesthetics Tech Forum 2023 LaunchPad Small Business Development Center (SBDC) accelerator program. (Stay tuned for an upcoming feature on all the companies that participated in LaunchPad in 2023.)
In addition, the study showed safety, volume retention, skin quality improvement, as well as positive patient FACE-Q Satisfaction outcome scoring compared to pre-treatment.
More than 20 patients were enrolled in the study for the correction of age-related cheeks and nasolabial fold volume deficit. Based on the FACE-Q Satisfaction with Facial Appearance Overall scale results, pre-treatment entry scores indicated that, on average, patients were very dissatisfied or somewhat dissatisfied, with aspects of their facial appearance. After receiving treatment to the cheeks and nasolabial folds, 82% of patients reported being very satisfied or somewhat satisfied with their facial appearance, the study showed.
“We are thrilled by these results, as they are a testament to the SyntrFuge system’s ability to deliver predictable outcomes for patients,” says plastic surgeon and clinical study investigator Dr. Hisham Seify, MD, PhD, FACS, in a news release. “The data validates the effectiveness of SyntrFuge processed fat tissue as a long-term solution, while maintaining optimal volume retention and achieving natural-looking results for patients.”
“The ability to use your own fat tissue as a natural solution to fillers is growing and patients are seeing firsthand the positive outcomes with our SyntrFuge processed fat. We are committed to delivering innovative solutions to ensure that fat is transferred with maximum viability and minimal loss in-order to meet the needs of patients and physicians,” adds Ahmed Zobi, CEO of Syntr Health. “This first-of-its-kind clinical study is just the beginning, and we look forward to continuing to advance the field of fat transfer.”
